Observational Study to Evaluate Fertility in Women Between 32 and 38 Years Old Treated With the Ovosicare® Fertility
Prospective Observational Study to Evaluate Fertility in Women Between 32 and 38 Years Old Treated With the Ovosicare® Fertility Food Supplement Containing a Combination of MYO/DCI in a 3.6:1 Ratio, Antioxidants, Vitamins and Minerals
Procare Health Iberia S.L.
300 participants
Feb 13, 2025
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to evaluate whether supplementation with the Ovosicare® Fertility food supplement increases the possibility of becoming pregnant in women aged between 32 and 38 years who have been trying to become pregnant for at least 6 months before starting supplementation.
Eligibility
Inclusion Criteria3
- \- Women who agree to participate in the study by signing the informed consent.
- \- Between 32 and 38 years old.
- \- Who come to doctor´s office stating that they have been trying to get pregnant for at least 6 months.
Exclusion Criteria15
- \- BMI > 30 kg/m2.
- \- Existence of severe male factor subfertility according to the criteria of the World Health Organization (WHO), with at least one analysis obtained in the last 6 months with one or more variables with values of:
- Azoospermia
- Progressive motility <25%
- Normal morphology ≤2%
- \- Pregnant or breastfeeding women.
- \- Patients with type 1 diabetes or thyroid disease.
- \- Patients with any assisted reproduction technique scheduled during the duration of the study.
- \- Patients who have used or taken systemic steroids, anticonvulsants, antiretroviral treatment for HIV or hepatitis B in the last month.
- \- Patients with a known allergy to any of the components of Ovosicare® Fertility.
- \- Any other situation that, in the medical opinion, advises against treatment with Ovosicare® Fertility or that may make patient follow-up difficult.
- \- Patients with suspected endometriosis.
- \- Existence of fibroids affecting the endometrial cavity.
- \- Patients with 2 or more previous abortions.
- \- Patients with a current diagnosis of a high-risk human papillomavirus (HPV) cervical lesion.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(27)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07083999